title: Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.
authors.forename: Trino
authors.initials: T
authors.lastname: Baptista
authors.forename: Maritza
authors.initials: M
authors.lastname: Martinez
authors.forename: Anny
authors.initials: A
authors.lastname: Lacruz
authors.forename: Antonio
authors.initials: A
authors.lastname: Arellano
authors.forename: Soaira
authors.initials: S
authors.lastname: Mendoza
authors.forename: Serge
authors.initials: S
authors.lastname: Beaulieu
authors.forename: Luis
authors.initials: L
authors.lastname: Hernández
authors.forename: Quilianio
authors.initials: Q
authors.lastname: Contreras
authors.forename: Tatiana
authors.initials: T
authors.lastname: Galeazzi
authors.forename: Doritza
authors.initials: D
authors.lastname: Vargas
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001066:Appetite / Q000187:drug effects; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D002908:Chronic Disease; D003692:Delayed-Action Preparations; D005260:Female; D005476:Fluphenazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D000077152:Olanzapine; D012016:Reference Values; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D015430:Weight Gain / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D003692:Delayed-Action Preparations; D007328:Insulin; D001569:Benzodiazepines; C011825:fluphenazine depot; D018967:Risperidone; D000077152:Olanzapine; D005476:Fluphenazine